Anti-TNF-α properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4-inhibiting properties

Biochemical and Biophysical Research Communications

Volumn 288, Issue 2, 2001, Pages 427-434

  Reimund, Jean Marie ^a,c   Raboisson, Pierre ^b   Pinna, Guillaume ^a   Lugnier, Claire ^a   Bourguignon, Jean Jacques ^b   Muller, Christian D ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b CNRS   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

3 ,5 cyclic adenosine monophosphate phosphodiesterase inhibitors; Adenines; Anti inflammatory agents; Cytokines; Human mononuclear cells; Tumor necrosis factor

Indexed keywords

9 BENZYLADENINE DERIVATIVE; ADENINE DERIVATIVE; ANTIINFLAMMATORY AGENT; BWA 78 U; DENBUFYLLINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; NCS 675; NCS 700; NCS 706; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PICLAMILAST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0035955298     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2001.5786     Document Type: Article

References (54)

1. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
2. PDE isoenzymes as targets for anti-asthma drugs
3. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney
4. Cyclic nucleotide phosphodiesterases (PDEs): Diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents
5. The role of phosphodiesterase enzymes in allergy and asthma
6. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents
7. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram
8. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor
9. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis
10. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice
11. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice
12. Protection against bloodbrain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: A quantitative study
13. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells
14. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation
15. The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents
16. 3H]rolipram binding activity and their relationship to emetic behavior in the ferret
17. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro antiinflammatory actions
18. 9-Benzyladenines: Potent and selective cAMP phosphodiesterase inhibitors
19. Suppression of anti-CD3-induced interleukin-4 and interleukin-5 release from splenocytes of Mesocestoides corti-infected BALB/c mice by phosph0diesterase 4 inhibitors
20. Effects of RP 73401, a novel, potent and selective phosphodiesterase type 4 inhibitor, on contractility of human, isolated bronchial muscle
21. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: Role in vasodilatation
22. 2+ influx by pentoxifylline in NR8383 alveolar macrophages
23. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand
24. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues
25. Inhibition of type 4 phosphodiesterase by rolipram and Ginkgo biloba extract (EGb 761) decreases agonist-induced rises in internal calcium in human endothelial cells
26. Monoclonal antibodies to human recombinant interleukin 1 (IL 1) beta: Quantitation of IL 1 beta and inhibition of biological activity
27. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease
28. Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells
29. Differential regulation of antigen-induced IL4 and IL-13 generation from T lymphocytes by IFN-alpha
30. Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation
31. Leukotriene D4 receptors are not negatively coupled to adenylyl cyclase in guinea-pig lung parenchyma
32. Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine
33. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis
34. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease
35. Learning abilities, NGF and BDNF brain levels in two lines of TNF-alpha transgenic mice, one characterized by neurological disorders, the other phenotypically normal
36. Cytokine blockade as a new strategy to treat rheumatoid arthritis: Inhibition of tumor necrosis factor
37. Etanercept in children with polyarticular juvenile rheumatoid arthritis
38. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
39. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression
40. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents
41. Phosphodiesterase IV inhibitors: Structural diversity and therapeutics potential in asthma
42. Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl) imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase
43. Anti-inflammatory effects of the novel phosphodiesterase IV inhibitor RP 73401
44. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B
45. Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding
46. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity
47. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo
48. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic
49. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-Chlorophenyl)-l,7-diethylpyrido
50. Zymosan-induced IL-8 release from human neutrophils involves activation via the CD11b/CD18 receptor and endogenous platelet-activating factor as an autocrine modulator
51. The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay
52. Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors
53. Lipopolysaccharide-induced cytokine production in peripheral blood mononuclear cells: Intracellular localization of tumor necrosis factor alpha and interleukin 1 beta detected with a three-color immunofluorescence technique
54. Suppression oflipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: Interaction with stimulants of adenylyl cyclase